The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data
Abstract
Nosocomial infections caused by extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacteria complicate therapy and limit treatment options. However, the clinical significance of infections caused by ESBL-producing bacteria remains unclear. A critical examination of the literature provides divergent views of the effect of ESBL carriage on morbidity and mortality and suggests that ESBL production may have its most marked effect on ceftazidime. Effective strategies for the empirical and directed treatment of infections caused by ESBL-producing pathogens include the use of carbapenems and, possibly, the fourth-generation cephalosporin cefepime. Studies indicate that the use of cefepime to treat serious nosocomial infections (e.g., bacteremia, pneumonia, and urinary tract infections) is associated with high rates of microbiological and clinical success. The probability of attaining time above the minimum inhibitory concentration targets of at least 70% of the dosing interval, an important pharmacodynamic indicator of clinical success, is higher with cefepime than with other antimicrobials against Escherichia coli and Klebsiella pneumoniae strains exhibiting ESBL phenotypes. However, for non-ESBL-producing strains, there is no difference in the time above the minimum inhibitory concentration between ceftazidime and cefepime. When used appropriately in institutional settings, cefepime reduces the overall use of cephalosporins, thereby decreasing selection pressure for presumptive ESBL-producing pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Lautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H., & Fishman, N. O. (2001) · Clinical Infectious Diseases · doi:10.1086/319757 · Cited by 747
Rahal, J. J. (1998) · JAMA · doi:10.1001/jama.280.14.1233 · Cited by 642
Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins
Meyer, K. S., Urban, C., Eagan, J. A., Berger, B. J., & Rahal, J. J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00001 · Cited by 580
Paterson, D. L., Ko, W.-C., Von Gottberg, A., Casellas, J. M., Mulazimoglu, L., Klugman, K. P., Bonomo, R. A., Rice, L. B., McCormack, J. G., & Yu, V. L. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2206-2212.2001 · Cited by 546
Winokur, P. L., Cantón, R., Casellas, J., & Legakis, N. J. (2001) · Clinical Infectious Diseases · doi:10.1086/320182 · Cited by 440
Guilt and dynamics of psychological disorder.
BRINKMANN, D., & Rickman, J. (1948) · PubMed · Cited by 417
Paterson, D. L., Mulazimoglu, L., Casellas, J. M., Ko, W.-C., Goossens, H., Von Gottberg, A., Mohapatra, S., Trenholme, G. M., Klugman, K. P., McCormack, J. G., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313719 · Cited by 386
Rice, L. B., Willey, S. H., Papanicolaou, G. A., Medeiros, A. A., Eliopoulos, G. M., Moellering, R. C., & Jacoby, G. A. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.11.2193 · Cited by 376
Kim, Y.-K., Pai, H., Lee, H.-J., Park, S.-E., Choi, E.-H., Kim, J., Kim, J.-H., & Kim, E.-C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1481-1491.2002 · Cited by 357
Rice, L. B., Eckstein, E. C., DeVente, J., & Shlaes, D. M. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.1.118 · Cited by 313
Paterson, D. L. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00107.x · Cited by 310
Standards for antimicrobial susceptibility testing.
Walker, R. D. (1999) · PubMed · Cited by 288
Schiappa, D. A., Hayden, M. K., Matushek, M. G., Hashemi, F. N., Sullivan, J., Smith, K. Y., Miyashiro, D., Quinn, J. P., Weinstein, R. A., & Trenholme, G. M. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.3.529 · Cited by 248
Lautenbach, E., Strom, B. L., Bilker, W. B., Patel, J. B., Edelstein, P. H., & Fishman, N. O. (2001) · Clinical Infectious Diseases · doi:10.1086/322667 · Cited by 227
Du, B., Long, Y., Liu, H., Chen, D., Liu, D., Xu, Y., & Xie, X. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1521-1 · Cited by 207
Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.-A., Bille, J., Aymon, D., Stratchounski, L., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3442-3447.2003 · Cited by 190
Quinn, J. P., Miyashiro, D., Sahm, D., Flamm, R., & Bush, K. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1451 · Cited by 187
Hoban, D. J., Biedenbach, D. J., Mutnick, A. H., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00540-0 · Cited by 136
Wong‐Beringer, A., Hindler, J. A., Loeloff, M. J., Queenan, A. M., Lee, N., Pegues, D. A., Quinn, J. P., & Bush, K. (2002) · Clinical Infectious Diseases · doi:10.1086/324742 · Cited by 125
Activity of levofloxacin and ciprofloxacin against urinary pathogens
Drago, L. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.37 · Cited by 97
Ambrose, P. G., Bhavnani, S. M., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1643-1646.2003 · Cited by 96
Quale, J. M., Landman, D., Bradford, P. A., Visalli, M. A., Ravishankar, J., Flores, C., Mayorga, D., Vangala, K., & Adedeji, A. (2002) · Clinical Infectious Diseases · doi:10.1086/342577 · Cited by 96
The Brooklyn Antibiotic Resistance Task Force (2002) · Infection Control and Hospital Epidemiology · doi:10.1086/502018 · Cited by 90
Mathai, D. C., Lewis, M. T., Kugler, K. C., Pfaller, M. A., & Jones, R. N. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00234-0 · Cited by 82
MYSTIC program: summary of European data from 1997 to 2000
Goossens, H. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(01)00320-0 · Cited by 63
Piperacillin/Tazobactam in the Treatment ofKlebsiella PneumoniaeInfections in Neonates
Pillay, T., Pillay, D. G., Adhikari, M., & Sturm, A. W. (1998) · American Journal of Perinatology · doi:10.1055/s-2007-993898 · Cited by 60
The inoculum effect: Fact or artifact?
Craig, W. A., Bhavnani, S. M., & Ambrose, P. G. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.07.006 · Cited by 58
García-Rodríguez, J. A., Jones, R. N., & And The Mystic Programme Study Group (2002) · Journal of Chemotherapy · doi:10.1179/joc.2002.14.1.25 · Cited by 55
CTX-M-14, a Plasmid-Mediated CTX-M Type Extended-Spectrum β-Lactamase Isolated from Escherichia coli
Ma, L., Ishii, Y., Chang, F., Yamaguchi, K., Ho, M., & Siu, L.-K. K. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1985-1988.2002 · Cited by 53
Yu, W., Jones, R. N., Hollis, R. J., Messer, S. A., Biedenbach, D. J., Deshpande, L. M., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.12.4666-4669.2002 · Cited by 37
Cited by
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
“resistant organisms, has been associated with use of broadspectrum cephalosporins and fluoroquinolones [22, 23].”
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-06 · Cited by 461
Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas, M. E., & Bliziotis, I. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.12.012 · Cited by 393
Pitout, J. D. D. (2010) · Drugs · doi:10.2165/11533040-000000000-00000 · Cited by 376
Metadata
- Authors
- Ramphal, R., & >, P. G. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-15
- Volume
- 42
- Issue
- Supplement_4
- Pages
- S164-S172
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168764308
- Cited by
- 267
- References
- 31
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.